Joseph Zola, MD
Urology · Oxford, NCNPI 1790973915
Payments from drug & device makers
Across 171 payments — averaging $22.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$607
- Astellas Pharma US Inc$540
- Sumitomo Pharma America, Inc.$521
- Pfizer$296
- Teleflex LLC$169
- Bayer$165
- plus $2K from 29 others
What the payments were for
- Food & beverage$3,35988%
- Education$45812%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson(2 entities) | 25 | $607 |
| Astellas Pharma US Inc | 22 | $540 |
| Sumitomo Pharma America, Inc. | 23 | $521 |
| Pfizer | 13 | $296 |
| Teleflex LLC | 7 | $169 |
| Bayer | 7 | $165 |
| Procept Biorobotics Corporation | 4 | $160 |
| Endo Pharmaceuticals Inc. | 7 | $126 |
| Laborie Medical Technologies Corp. | 3 | $124 |
| Olympus America Inc. | 4 | $97 |
| Medtronic | 4 | $92 |
| Endo USA, Inc. | 4 | $88 |
| Coloplast | 4 | $73 |
| Aytu Biopharma, Inc. | 4 | $73 |
| Axonics, Inc. | 4 | $72 |
| AbbVie(2 entities) | 5 | $67 |
| Tolmar, Inc. | 3 | $66 |
| Convatec Inc. | 3 | $63 |
| ABC Home Medical Supply, Inc. | 2 | $47 |
| Cycle Pharmaceuticals Inc | 2 | $44 |
| Antares Pharma, Inc. | 3 | $35 |
| Boston Scientific | 2 | $32 |
| Photonicare Inc | 1 | $32 |
| Smith+Nephew | 2 | $31 |
| Inspire Medical Systems, Inc. | 1 | $28 |
| Novartis | 1 | $28 |
| Calyxo, Inc. | 1 | $24 |
| Halozyme Inc | 1 | $20 |
| Pacira Pharmaceuticals Incorporated | 1 | $20 |
| Dendreon Pharmaceuticals LLC | 1 | $14 |
| Merck | 1 | $13 |
| Davol Inc. | 1 | $13 |
| Clarus Therapeutics Inc. | 3 | $13 |
| Urovant Sciences Inc | 1 | $13 |
| TEI Biosciences Inc | 1 | $11 |
How this compares
$3,817 in reported general payments places this provider in the 55th percentile of 434 urology providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XtandiEnzalutamide | 74 | $1,053,055 |
| GemtesaVibegron | 194 | $124,299 |
| MyrbetriqMirabegron | 173 | $107,844 |
| OrgovyxRelugolix | 29 | $77,891 |
| Tamsulosin Hcl | 1,237 | $20,670 |
| Fosfomycin Tromethamine | 13 | $20,092 |
| Finasteride | 1,192 | $16,391 |
| Potassium Citrate ErPotassium Citrate | 95 | $9,475 |
| Methenamine Hippurate | 106 | $9,038 |
| NitrofurantoinNitrofurantoin Macrocrystal | 122 | $8,349 |
| Cephalexin | 126 | $7,503 |
| Oxybutynin Chloride | 451 | $6,740 |
| Silodosin | 43 | $3,216 |
| Bethanechol Chloride | 35 | $2,968 |
| Desmopressin Acetate | 50 | $2,918 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncXtandi, Myrbetriq | $540 | $1,160,898247 claims |
| Sumitomo Pharma America, Inc.Gemtesa, Orgovyx | $521 | $202,190223 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 434 urology providers in North Carolina.
Other urology in Oxford
- Daniel GeorgeDurham$17.6M
- Robert LippittSmithfield$11.4M
- Thomas PolascikDurham$4.7M
- Judd MoulDurham$4.1M
- John WrennGreensboro$2.9M
- Michael KennellyCharlotte$1.4M
- John KasparRaleigh$1.1M
- Scott MacdiarmidGreensboro$882K
- Glenn PremingerDurham$736K
- Jonathan HamiltonGreenville$695K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.